Decreased coenzyme Q10 concentration in plasma of children with cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 5, 2006, Pages 646-650

  Oudshoorn, Johanna H ^a   Lecluse, Anne L Y ^a   Van Den Berg, Robin ^b   Vaes, Wouter H J ^b   Van Der Laag, Johan ^a   Houwen, Roderick H J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Coenzyme Q10; Cystic fibrosis

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; UBIDECARENONE;

ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; LUNG DISEASE; MALABSORPTION; MALE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 33845255015     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000233193.77521.66     Document Type: Article

References (36)

1. Kalin A, Norling B, Appelkvist EL, et al. Ubiquinone synthesis in the microsomal fraction of rat liver. Biochim Biophys Acta 1987;926:70-8.
2. 10 content. Mol Aspects Med 1997;18:S105-12.
3. Crane FL, Navas P. The diversity of coenzyme Q function. Mol Aspects Med 1997;18S:S1-6.
4. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204.
5. 10 in human plasma as possible marker of oxidative stress. J Lipid Res 1996;37:67-75.
6. Winklhofer-Roob BM, Puhl H, Khoschsorur G, et al. Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during β-carotene supplementation in cystic fibrosis. Free Radic Biol Med 1995;18:849-59.
7. Winklhofer-Roob BM, Ziouzenkova O, Puhl H, et al. Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. Free Radic Biol Med 1995;19:725-33.
8. Kamei M, Fujita T, Kanbe T, et al. The distribution and content of ubiquinone in foods. Int J Vitam Nutr Res 1986;56:57-63.
9. 10 in plasma, erythrocytes and platelets: comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin Chim Acta 2004;342:219-26.
10. Zhang Y, Aberg F, Appelkvist EL, et al. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 1995;125:446-53.
11. 10. J Am Coll Nutr 2001;20:591-8.
12. Stocker R, Bowry VW, Frei B. Ubiquinone 10 protects human low density lipoprotein more effectively against lipid peroxidation than tocopherol. Proc Natl Acad Sci U S A 1991;88:1646-50.
13. Constantinescu A, Maquire JJ, Packer L. Interactions between ubiquinones and vitamins in membranes and cells. Mol Aspects Med 1994;15:S57-67.
14. Ratjen F, Doring G. Cystic Fibrosis. Lancet 2003;361:681-9.
15. Jaffe A, Bush A. Cystic fibrosis: review of the decade. Monaldi Arch Chest Dis 2001;56:240-7.
16. Langley SC, Brown RK, Kelly FJ. Reduced free-radical-trapping capacity and altered antioxidant status in cystic fibrosis. Pediatr Res 1993;33:247-50.
17. Brown RK, Kelly FJ. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 1994;49:738-42.
18. Lands LC, Grey VL, Grenier C. Total plasma antioxidant capacity in cystic fibrosis. Pediatr Pulmonol 2000;29:81-7.
19. Winklhofer-Roob BM. Antioxidant status in cystic fibrosis patients. Am J Clin Nutr 1996;63:138-9.
20. Dominguez C, Gartner S, Linan S, et al. Enhanced oxidative damage in cystic fibrosis patients. Biofactors 1998;8:149-53.
21. Brown RK,Wyatt H, Price JF, et al. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J 1996;9:334-9.
22. Fririks AM, van Buuren S, Burgmeijer RJF, et al. Continuing positive secular growth change in the Netherlands 1955-1997. Pediatr Res 2000;47:316-23.
23. Klijn PH, Terheggen-Lagro SW, van der Ent CK, et al. Anaerobic exercise in pediatric cystic fibrosis. Pediatr Pulmonol 2003;36:223-9.
24. 10 concentrations in children with cystic fibrosis. Pediatr Pulmonol 2003;25:338. Abstract.
25. Lagendijk J, Ubbink JB, Delport R, et al. Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease. Res Commun Mol Pathol Pharmacol 1997;95:11-20.
26. Kontush A, Reich A, Baum K, et al. Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. Atherosclerosis 1997;129:119-26.
27. 10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 2004;223:161-6.
28. 10 in Parkinson's disease. J Neural Transm 2000;107:41-8.
29. Yamamoto Y, Yamashita S. Plasma ubiquinone and ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. Biofactors 1999;9:241-6.
30. 10 in children with hyperthyreoidism. Horm Res 2004;61:153-8.
31. Artuch R, Vilaseca MA, Moreno J, et al. Decreased serum ubiquinone-10 concentrations in phenylketonuria. Am J Clin Nutr 1999;70:892-5.
32. 10 and lipids in patients during total parenteral nutrition. J Nutr Sci Vitaminol (Tokyo) 1986;32:1-12. Abstract.
33. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002;1:51-75.
34. Benabdeslam H, Abidi H, Garcia I, et al. Lipid peroxidation and antioxidant defences in cystic fibrosis patients. Clin Chem Lab Med 1999;37:511-6.
35. 10 for two months in a randomised controlled study. Biofactors 2003;18 (1-4):185-93.
36. 10 administration on pulmonary function and exercise performance in patients with chronic lung disease. Clin Invest 1993;71:S161-6.